What guidance did Imunon's management provide for the next earnings period?

What factors drove the changes in Imunon's revenue and profit?

What is the revenue and EPS growth rate for Imunon year over year?

What were the key takeaways from Imunon’s earnings call?

What is the market's earnings forecast for Imunon next quarter?

What is Imunon's gross profit margin?

What is Imunon's latest dividend and current dividend yield?

What does Imunon do and what are its main business segments?

- **OVATION 3 Enrollment Surging**: 9 patients randomized by October 2025, exceeding internal targets.
- **Cost Efficiency**: 31% YoY drop in operating expenses, $1.25M monthly cash burn.
- **Adaptive Trial Design**: 95% statistical power with interim stopping rules for accelerated approval.
- **Regulatory Momentum**: FDA-endorsed overall survival endpoint, European alignment in sight.
- **Partnership Progress**: Active discussions with pharma companies for non-dilutive funding.

**【CEO Summary Section】**
- **OVATION 3 Trial Progress**: Enrollment ahead of target with 9 patients randomized by end of October 2025, surpassing internal targets. Site activation in the U.S. is deliberate to align with cash position, with plans to surge activations in 2026.
- **Regulatory Milestones**: FDA endorsement of overall survival as a single study registration endpoint. European regulatory alignment expected based on trial design and outcomes.
- **Financial Management**: Monthly cash burn reduced to $1.25-$1.5 million, with operating expenses down 31% year-over-year. Focus on nondilutive partnerships and ATM facility usage to extend runway into mid-2026.

**【CFO Financial Commentary】**
- **Cash Position**: $5.3 million as of Q3 2025, supporting operations into mid-2026.
- **Expense Reduction**: R&D expenses down 44% YoY, G&A down 52%, driven by streamlined operations and site activation prioritization.
- **Net Loss**: $3.4 million for Q3 2025, reflecting reduced trial costs and cost-cutting measures.

**【Q&A Highlights】**
- **Interim Analysis Design**: Adaptive event-driven study with 95% power to detect survival benefit. P-value thresholds dynamically adjusted based on information fraction, ensuring type 1 error control.
- **Site Activation Strategy**: 40% cost savings by prioritizing HRD-positive subgroup in 500-patient trial. CRO engagement to accelerate site start-ups globally.
- **Pain Management Protocol**: Prophylactic analgesia mandated across all sites to mitigate peritoneal discomfort, with no systemic IL-12 exposure reported.
- **Regulatory Pathway**: Full approval potential for HRD-positive subgroup with interim success, broader label pending final analysis.

Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript

- **Trial Momentum**: OVATION 3 enrollment pace exceeds industry benchmarks, with 15-week activation vs. 28-week industry average.
- **HRD Subset Focus**: 50% of frontline patients benefit from PARP inhibitor integration, with median OS of >5 years vs. 37 months control arm.
- **Cost-Effective Design**: 40% cost reduction for HRD-positive subgroup, enabling faster efficacy signal detection.
- **Immune Response**: Local cytokine activation drives durable antitumor activity without systemic toxicity.

**【CEO Summary Section】**
- **Phase III Trial Progress**: IMNN-001's pivotal OVATION 3 trial achieved 15-week activation (industry benchmark: 28 weeks), with first patient enrolled on July 25, 2025. The trial focuses on HRD-positive patients (50% of frontline ovarian cancer population) to accelerate efficacy signals. Secondary endpoints include quality-of-life measures for payer discussions.
- **Financial Strategy**: Introduced a 15% stock dividend to minimize dilution and enhance liquidity. Implemented cost-saving measures (e.g., reduced G&A expenses by 32% YoY) and raised $3M via warrants and ATM in Q2. Seeking partnerships to fund Phase III without excessive equity issuance.
- **Regulatory Compliance**: On track to meet NASDAQ's $1 bid price requirement by August 8, 2025, with plans to update the hearing panel on compliance progress.

**【CFO Financial Commentary】**
- **Cash Position**: $4.7M as of June 30, 2025, with post-Q2 net proceeds of $3M from warrant exercises and ATM sales. R&D expenses down 57% YoY due to OVATION 2 completion and reduced PlaCCine trial costs. G&A expenses down 32% YoY, driven by lower employee-related and legal costs. Net loss of $2.7M, 44% lower than Q2 2024, with per-share loss of $2.15 (adjusted for 15-for-1 reverse split).

**【Q&A Highlights】**
- **Patient Enrollment Momentum**: Investigators report strong demand, with 13 months median OS improvement in IMNN-001 arm (HRD-positive subgroup shows 45% hazard ratio reduction vs. control, with PARP inhibitor use extending median OS to >5 years).
- **Cost Efficiency**: Central lab testing reduces costs by 40% for HRD-positive subset, enabling early stopping for efficacy milestones.
- **Partnership Interest**: Global investigators are prioritizing IMNN-001 due to its tumor-targeted IL-12 therapy, which avoids systemic toxicity and enhances tumor microenvironment immune infiltration (e.g., 46-month OS vs. 33-month control, 46% improvement).

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

- **Phase III Trial Launched**: First site activated for IMNN-001 in ovarian cancer, targeting HRD-positive subgroup for faster readout.
- **Strong Clinical Data Momentum**: OVATION 2 results to be presented at ASCO and published, highlighting IL-12's safety and efficacy.
- **Financial Focus**: $2.9M cash runway, seeking partnerships to fund trial without dilution.
- **Manufacturing Confidence**: In-house API production ensures product availability for enrollment.

**【CEO Summary Section】**
- Launched Phase III OVATION 3 trial for IMNN-001 in ovarian cancer, with first clinical site activated.
- Phase II OVATION 2 data to be presented at ASCO 2025 as oral session and published in Gynecologic Oncology.
- Focused on HRD-positive subgroup (BRCA1/2 mutation) with 250-patient trial, aiming for 2-year earlier readout vs full 500-patient study.
- Seeking partnerships to secure $2.9M cash runway and cover trial costs without dilution.

**【CFO Financial Commentary】**
- Q1 2025 cash balance: $2.9M (down from $3.2M in Q4 2024).
- R&D expenses: $2.2M (down 33% YoY due to reduced PlaCCine trial costs).
- G&A expenses: $2.0M (up 18% YoY due to higher employee costs).
- Net loss: $4.1M (vs $4.9M YoY), driven by lower R&D spend.

**【Q&A Key Takeaways】**
- Manufacturing: In-house API production ready for trial, no supply chain risks.
- Site expansion: 45+ sites planned, with University of Oklahoma and Johns Hopkins leading recruitment.
- Break Through Cancer trial: On track for 2025 interim results with 18+ sites active.
- ASCO presentation: embargoed details, but emphasizes IL-12 safety profile and translational data.

Imunon (IMNN)-12 May 25-2025 Q1 Earnings call transcript

- **Breakthrough Ovarian Cancer Data**: IMNN-001 extended median OS to 13 months vs. 37.1 months in control, with a 0.69 hazard ratio in Phase II. Phase III trial (500 pts) starts Q1 2025.
- **IL-12 Delivery Innovation**: TheraPlas platform achieves tumor-localized cytokine production with no systemic toxicity, a first for IL-12 therapies.
- **Financial Resilience**: $5.9M cash runway to Q2 2025; exploring partnerships and financing to support Phase III completion.
- **Vaccine Potential**: IMNN-001 COVID booster showed 2-4x neutralizing antibodies, with stability advantages over mRNA vaccines.
- **Cost Efficiency**: Internal API manufacturing reduces costs by 90%, positioning for strong commercial margins if approved.


**【CEO Opening Remarks】**
- 2024 was a transformative year with the successful completion of the Phase II OVATION 2 study for IMNN-001 in ovarian cancer. The trial showed a median overall survival (OS) of 13 months vs. 37.1 months in the control arm, with a hazard ratio of 0.69 in the intent-to-treat population.
- IMNN-001 is set to initiate a pivotal Phase III study (OVATION 3) in Q1 2025, targeting 500 patients with newly diagnosed advanced ovarian cancer. The trial will use a 100 mg/m² dose, supported by translational data showing a 20% higher IL-12 level compared to lower doses.
- The company is exploring accelerated approval pathways with the FDA, leveraging the Phase II data and the ongoing Phase III trial's confirmatory potential.

**【CMO Clinical Update】**
- OVATION 2 demonstrated a strong safety profile with no cytokine release syndrome or dose-limiting toxicities. Patients receiving ≥20% of planned doses saw a 17-month OS improvement.
- Translational data showed a dose-dependent IL-12 response in the tumor microenvironment, with downstream anti-cancer cytokines like interferon-gamma and TGF-alpha increasing significantly.
- The Phase III trial design mirrors OVATION 2, with primary endpoints of OS in HR-deficient and intent-to-treat populations, powered at 95% and higher, respectively.

**【CFO Financial Overview】**
- Cash balance as of Dec 31, 2024: $5.9M, supporting operations into Q2 2025.
- R&D expenses: $11.6M (up 3% vs. 2023) due to OVATION 2 and OVATION 3 start-up costs.
- G&A expenses: $7.5M (down 23% vs. 2023) from reduced professional fees and headcount.
- Net loss: $18.6M ($1.62/sh) vs. $19.5M ($2.16/sh) in 2023.

**【Q&A Key Takeaways】**
- **Partnership Strategy**: Exploring non-dilutive funding via TheraPlas technology licensing and geographic partnerships, with a focus on IL-12 combination therapies.
- **COVID Vaccine Data**: IMNN-001 showed 2-4x neutralizing antibody titers vs. baseline, with a safety profile superior to mRNA vaccines. Seeking partners for PlaCCine-based cancer vaccines.
- **Trial Enrollment**: OVATION 3 aims to enroll 500 patients by end-2025, with 35 patients expected in 2025. The MRD combination study (with Avastin) has accelerated enrollment to 35/50 targets.
- **Cash Runway**: Actively pursuing financing to extend cash runway beyond Q2 2025, with discussions with oncology-focused investors.

**【Technology Highlights】**
- TheraPlas platform enables localized IL-12 delivery with no systemic toxicity, a first-in-class approach for ovarian cancer immunotherapy.
- Internal GMP manufacturing reduces API costs by ~90%, positioning IMNN-001 for attractive commercial margins.
- PlaCCine technology demonstrated superior stability and thermal tolerance vs. mRNA vaccines, with potential for next-gen cancer vaccines.


Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Imunon (IMNN)-7 Nov 24-2024 Q3 Earnings call transcript

Imunon (IMNN)-14 Aug 24-2024 Q2 Earnings call transcript

Imunon (IMNN)-13 May 24-2024 Q1 Earnings call transcript

Imunon (IMNN)-28 Mar 24-2023 Q4 Earnings call transcript

**Key Takeaways**
- **Clinical Success**: IMNN-001 shows transformative 8-month PFS improvement in ovarian cancer, positioning for potential registration.
- **Vaccine Innovation**: PLACCINE platform demonstrates superior stability and immune response, with IMNN-101 entering clinic in Q2 2024.
- **Financial Strength**: $19.5M cash, 38% expense reduction, and $4M/Q cash burn ensure 12+ months of runway.
- **Strategic Growth**: NIH collaborations, Alabama manufacturing, and AI-driven antigen discovery accelerate pipeline expansion.

**【CEO Summary Section】**
- **IMNN-001 Phase II Results**: IMNN-001 combined with PARP inhibitors showed an 8-month PFS improvement (23.7 vs. 15.7 months) and ongoing OS benefit. ITT population hazard ratio of 0.78 (80% CI) suggests potential for registration. Secondary endpoints included 20% higher tumor resection scores and 30% chemotherapy response rates.
- **PLACCINE Vaccine Progress**: IMNN-101, a COVID-19 booster, targets IND submission in Q1 2024 and Phase I/II trials starting April 2024. Preclinical data highlight superior antigen expression, T-cell responses, and stability (12 months at 4°C, 2 weeks at 37°C). NIH collaboration on LASSA virus vaccines and Wistar Institute partnership for Marburg virus vaccines expand pipeline.
- **Manufacturing Expansion**: New Alabama facility enables in-house production, reducing costs and reliance on third parties.

**【CFO Financial Commentary】**
- **Financial Position**: $19.5M cash as of Q3 2023. Net loss of $3.5M (down 42% YoY). Operating expenses decreased 38% to $3.9M, driven by lower R&D and G&A costs. Cash usage projected at $4M/Q for 2024.
- **Liquidity**: Sufficient funds for 12+ months. $1.8M expected from New Jersey NOL sales. No debt outstanding.

**【Q&A Key Highlights】**
- **OVATION-2 Next Steps**: FDA discussions for potential breakthrough designation. Mid-2024 top-line data expected. Focus on PARP inhibitor-combined subgroup analysis.
- **Avastin Trial Progress**: Phase I safety data anticipated Q2 2024. Dana-Farber and MSK sites activating soon. MRD reduction and PFS endpoints to guide future trials.
- **PLACCINE Expansion**: Exploring partnerships for seasonal flu and personalized cancer vaccines. AI-driven antigen identification to accelerate development.
- **Cost Management**: Tight control on R&D (down 40% YoY) and G&A (down 50% YoY) supports extended runway.

Actual											-39.1304	-35.2174	-46.9565	-9.7826	-17.6087	-11.7391	-11.7391	-8.8696	-23.7391	-11.3478	-11.3478	-19.1739	-8.8696	-7.9565	-4.8261	-6.5217	-6.7826	-6.6522	-4.4348	-3.2609	-3.6522	-1.8696	-1.16
Forecast											-33.2609	-27.3913	-15.6522	-25.4348	-11.7391	-15.6522	-16.6304	-11.7391	-13.1739	-14.6413	-10.5652	-11.087	-8.5435	-9.1957	-8.6087	-7.6522	-7.3913	-7.0435	-5.0609	-4.6696	-4.5652	-4.1413	-1.1986	-1.41
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-17.65%	-28.57%	-200.00%	+61.54%	-50.00%	+25.00%	+29.41%	+24.44%	-80.20%	+22.49%	-7.41%	-72.94%	-3.82%	+13.48%	+43.94%	+14.77%	+8.24%	+5.56%	+12.37%	+30.17%	+20.00%	+54.85%	+3.22%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	125.00K	125.00K	125.00K	125.00K	125.00K	125.00K	125.00K	110.00K	125.00K	125.00K	125.00K	125.00K	0	0	0	0	0	0	0	0	0	0	0	--
Forecast	--	--	--	--	--	--	--	--	--	--	127.50K	127.50K	130.00K	125.00K	125.00K	125.00K	112.50K	112.50K	108.33K	108.33K	108.33K	116.67K	62.50K	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.96%	-1.96%	-3.85%	0.00%	0.00%	0.00%	+11.11%	-2.22%	+15.38%	+15.38%	+15.38%	+7.14%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

IMNN

IMNN fundamentals

IMNN Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

IMNN

IMNN fundamentals

IMNN Q4 2025 Earnings Preview

Earnings Call

IMNN Earnings Call Summary for Q4/2025Upcoming11:00 AM on Mar 31, 2026

IMNN Earnings Call Summary for Q3/202511:00 AM on Nov 13, 2025

IMNN Earnings Call Summary for Q2/202511:00 AM on Aug 5, 2025

IMNN Earnings Call Summary for Q1/202511:00 AM on May 12, 2025

IMNN Earnings Call Summary for Q4/202411:00 AM on Feb 26, 2025

You can ask Aime